Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00250445 |
The study is designed to compare the risk of cardiovascular events (heart attacks, strokes) in patients receiving either etoricoxib or diclofenac. It will also compare the gastrointestinal tolerability of the two medicines. The study will be conducted in patients with either rheumatoid or osteo-arthritis.
Condition | Intervention | Phase |
---|---|---|
Rheumatoid Arthritis,Osteoarthritis |
Drug: MK0663, etoricoxib Drug: Comparator: Diclofenac sodium |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety Study |
Official Title: | A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis |
Estimated Enrollment: | 23500 |
Study Start Date: | September 2002 |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2005_100 |
Study First Received: | November 7, 2005 |
Last Updated: | May 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00250445 |
Health Authority: | United States: Food and Drug Administration |
Arcoxia |
Autoimmune Diseases Musculoskeletal Diseases Osteoarthritis Joint Diseases Arthritis |
Etoricoxib Connective Tissue Diseases Arthritis, Rheumatoid Diclofenac Rheumatic Diseases |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Immune System Diseases Physiological Effects of Drugs Cyclooxygenase Inhibitors Enzyme Inhibitors Pharmacologic Actions Analgesics, Non-Narcotic |
Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |